{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,29]],"date-time":"2026-10-29T18:10:48Z","timestamp":1793297448751,"version":"4.5.0"},"reference-count":63,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,12,4]],"date-time":"2023-12-04T00:00:00Z","timestamp":1701648000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81374051"],"award-info":[{"award-number":["81374051"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81873078"],"award-info":[{"award-number":["81873078"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82074109"],"award-info":[{"award-number":["82074109"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82374133"],"award-info":[{"award-number":["82374133"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Pharmacological Research"],"published-print":{"date-parts":[[2024,1]]},"DOI":"10.1016\/j.phrs.2023.107031","type":"journal-article","created":{"date-parts":[[2023,12,5]],"date-time":"2023-12-05T17:58:27Z","timestamp":1701799107000},"page":"107031","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":32,"special_numbering":"C","title":["Evaluation and comparison of efficacy and safety of tirzepatide and semaglutide in patients with type 2 diabetes mellitus: A Bayesian network meta-analysis"],"prefix":"10.1016","volume":"199","author":[{"given":"Yanan","family":"Ding","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yufei","family":"Shi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ruifang","family":"Guan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shiwei","family":"Yan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haiyang","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zihan","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiyifan","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tiandian","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Weimin","family":"Cai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guo","family":"Ma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.phrs.2023.107031_bib1","unstructured":"Dianna J. Magliano, Edward J. Boyko, IDF DIABETES ATLAS, 2021."},{"key":"10.1016\/j.phrs.2023.107031_bib2","doi-asserted-by":"crossref","first-page":"1803","DOI":"10.1016\/S0140-6736(22)01655-5","article-title":"Type 2 diabetes","volume":"400","author":"Ahmad","year":"2022","journal-title":"Lancet"},{"key":"10.1016\/j.phrs.2023.107031_bib3","doi-asserted-by":"crossref","first-page":"2753","DOI":"10.2337\/dci22-0034","article-title":"Management of Hyperglycemia in Type 2 Diabetes, 2022. A Consensus Report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD)","volume":"45","author":"Davies","year":"2022","journal-title":"Diabetes Care"},{"key":"10.1016\/j.phrs.2023.107031_bib4","doi-asserted-by":"crossref","first-page":"740","DOI":"10.1016\/j.cmet.2018.03.001","article-title":"Mechanisms of action and therapeutic application of glucagon-like peptide-1","volume":"27","author":"Drucker","year":"2018","journal-title":"Cell Metab."},{"key":"10.1016\/j.phrs.2023.107031_bib5","doi-asserted-by":"crossref","first-page":"1242","DOI":"10.1111\/dom.12932","article-title":"Effects of once\u2010weekly semaglutide on appetite, energy intake, control of eating, food preference and body weight in subjects with obesity","volume":"19","author":"Blundell","year":"2017","journal-title":"Diabetes Obes. Metab."},{"key":"10.1016\/j.phrs.2023.107031_bib6","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1007\/s40265-018-0871-0","article-title":"Semaglutide: first global approval","volume":"78","author":"Dhillon","year":"2018","journal-title":"Drugs"},{"key":"10.1016\/j.phrs.2023.107031_bib7","doi-asserted-by":"crossref","first-page":"2100","DOI":"10.1016\/j.clinthera.2020.07.017","article-title":"Oral semaglutide: the first-available noninjectable glucagon-like peptide 1 receptor agonist","volume":"42","author":"Powell","year":"2020","journal-title":"Clin. Ther."},{"key":"10.1016\/j.phrs.2023.107031_bib8","doi-asserted-by":"crossref","DOI":"10.1016\/j.dsx.2022.102511","article-title":"Semaglutide for the treatment of type 2 diabetes mellitus: a systematic review and network meta-analysis of safety and efficacy outcomes","volume":"16","author":"Zaazouee","year":"2022","journal-title":"Diabetes Metab. Syndr.: Clin. Res. Rev."},{"key":"10.1016\/j.phrs.2023.107031_bib9","article-title":"Safety of semaglutide","volume":"12","author":"Smits","year":"2021","journal-title":"Front, Endocrinol. (Lausanne)"},{"key":"10.1016\/j.phrs.2023.107031_bib10","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1038\/s41574-022-00783-3","article-title":"Beyond the pancreas: contrasting cardiometabolic actions of GIP and GLP1","volume":"19","author":"Hammoud","year":"2023","journal-title":"Nat. Rev. Endocrinol."},{"key":"10.1016\/j.phrs.2023.107031_bib11","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1016\/j.tem.2020.02.006","article-title":"How may GIP enhance the therapeutic efficacy of GLP-1?","volume":"31","author":"Samms","year":"2020","journal-title":"Trends Endocrinol. Metab."},{"key":"10.1016\/j.phrs.2023.107031_bib12","doi-asserted-by":"crossref","first-page":"2545","DOI":"10.2337\/db21-0459","article-title":"GIP receptor agonism attenuates GLP-1 receptor agonist\u2013induced nausea and emesis in preclinical models","volume":"70","author":"Borner","year":"2021","journal-title":"Diabetes"},{"key":"10.1016\/j.phrs.2023.107031_bib13","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2022.998816","article-title":"Efficacy and safety of tirzepatide in patients with type 2 diabetes mellitus: a bayesian network meta-analysis","volume":"13","author":"Guan","year":"2022","journal-title":"Front Pharm."},{"key":"10.1016\/j.phrs.2023.107031_bib14","doi-asserted-by":"crossref","first-page":"1213","DOI":"10.1007\/s40265-022-01746-8","article-title":"Tirzepatide: first approval","volume":"82","author":"Syed","year":"2022","journal-title":"Drugs"},{"key":"10.1016\/j.phrs.2023.107031_bib15","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1056\/NEJMoa2107519","article-title":"Tirzepatide versus semaglutide once weekly in patients with type 2 diabetes","volume":"385","author":"Fr\u00edas","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.phrs.2023.107031_bib16","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1002\/jrsm.1054","article-title":"Automating network meta-analysis","volume":"3","author":"van Valkenhoef","year":"2012","journal-title":"Res Synth. Methods"},{"key":"10.1016\/j.phrs.2023.107031_bib17","doi-asserted-by":"crossref","first-page":"n71","DOI":"10.1136\/bmj.n71","article-title":"The PRISMA 2020 statement: an updated guideline for reporting systematic reviews","author":"Page","year":"2021","journal-title":"BMJ"},{"key":"10.1016\/j.phrs.2023.107031_bib18","doi-asserted-by":"crossref","first-page":"777","DOI":"10.7326\/M14-2385","article-title":"The PRISMA extension statement for reporting of systematic reviews incorporating network meta-analyses of health care interventions: checklist and explanations","volume":"162","author":"Hutton","year":"2015","journal-title":"Ann. Intern Med"},{"key":"10.1016\/j.phrs.2023.107031_bib19","doi-asserted-by":"crossref","first-page":"l4898","DOI":"10.1136\/bmj.l4898","article-title":"RoB 2: a revised tool for assessing risk of bias in randomised trials","author":"Sterne","year":"2019","journal-title":"BMJ"},{"key":"10.1016\/j.phrs.2023.107031_bib20","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1016\/j.jclinepi.2010.03.016","article-title":"Graphical methods and numerical summaries for presenting results from multiple-treatment meta-analysis: an overview and tutorial","volume":"64","author":"Salanti","year":"2011","journal-title":"J. Clin. Epidemiol."},{"key":"10.1016\/j.phrs.2023.107031_bib21","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1136\/bmjebm-2018-111107","article-title":"Catalogue of bias: publication bias","volume":"24","author":"DeVito","year":"2019","journal-title":"BMJ Evid. Based Med."},{"key":"10.1016\/j.phrs.2023.107031_bib22","doi-asserted-by":"crossref","first-page":"1202","DOI":"10.1111\/dom.13218","article-title":"Safety and efficacy of once\u2010weekly semaglutide vs additional oral antidiabetic drugs in Japanese people with inadequately controlled type 2 diabetes: a randomized trial","volume":"20","author":"Kaku","year":"2018","journal-title":"Diabetes Obes. Metab."},{"key":"10.1016\/j.phrs.2023.107031_bib23","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1016\/S2213-8587(20)30075-9","article-title":"Dose-response, efficacy, and safety of oral semaglutide monotherapy in Japanese patients with type 2 diabetes (PIONEER 9): a 52-week, phase 2\/3a, randomised, controlled trial","volume":"8","author":"Yamada","year":"2020","journal-title":"Lancet Diabetes Endocrinol."},{"key":"10.1016\/j.phrs.2023.107031_bib24","doi-asserted-by":"crossref","first-page":"1466","DOI":"10.1001\/jama.2019.2942","article-title":"Effect of additional oral semaglutide vs sitagliptin on glycated hemoglobin in adults with type 2 diabetes uncontrolled with metformin alone or with sulfonylurea","volume":"321","author":"Rosenstock","year":"2019","journal-title":"JAMA"},{"key":"10.1016\/j.phrs.2023.107031_bib25","doi-asserted-by":"crossref","first-page":"1788","DOI":"10.1111\/dom.14765","article-title":"Effect of once\u2010weekly semaglutide versus thrice\u2010daily insulin aspart, both as add\u2010on to metformin and optimized insulin glargine treatment in participants with type 2 diabetes (SUSTAIN 11): a randomized, open\u2010label, multinational, phase 3b trial","volume":"24","author":"Kellerer","year":"2022","journal-title":"Diabetes Obes. Metab."},{"key":"10.1016\/j.phrs.2023.107031_bib26","doi-asserted-by":"crossref","first-page":"1460","DOI":"10.1001\/jama.2017.14752","article-title":"Effect of oral semaglutide compared with placebo and subcutaneous semaglutide on glycemic control in patients with type 2 diabetes","volume":"318","author":"Davies","year":"2017","journal-title":"JAMA"},{"key":"10.1016\/j.phrs.2023.107031_bib27","doi-asserted-by":"crossref","first-page":"534","DOI":"10.1001\/jama.2022.0078","article-title":"Effect of subcutaneous tirzepatide vs placebo added to titrated insulin glargine on glycemic control in patients with type 2 diabetes","volume":"327","author":"Dahl","year":"2022","journal-title":"JAMA"},{"key":"10.1016\/j.phrs.2023.107031_bib28","doi-asserted-by":"crossref","first-page":"774","DOI":"10.1111\/jdi.14000","article-title":"Effects of switching from liraglutide to semaglutide or dulaglutide in patients with type 2 diabetes: a randomized controlled trial","volume":"14","author":"Iijima","year":"2023","journal-title":"J. Diabetes Invest."},{"key":"10.1016\/j.phrs.2023.107031_bib29","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1016\/S0140-6736(21)01324-6","article-title":"Efficacy and safety of a novel dual GIP and GLP-1 receptor agonist tirzepatide in patients with type 2 diabetes (SURPASS-1): a double-blind, randomised, phase 3 trial","volume":"398","author":"Rosenstock","year":"2021","journal-title":"Lancet"},{"key":"10.1016\/j.phrs.2023.107031_bib30","doi-asserted-by":"crossref","first-page":"2180","DOI":"10.1016\/S0140-6736(18)32260-8","article-title":"Efficacy and safety of LY3298176, a novel dual GIP and GLP-1 receptor agonist, in patients with type 2 diabetes: a randomised, placebo-controlled and active comparator-controlled phase 2 trial","volume":"392","author":"Frias","year":"2018","journal-title":"Lancet"},{"key":"10.1016\/j.phrs.2023.107031_bib31","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1016\/j.diabet.2019.101117","article-title":"Efficacy and safety of once-weekly semaglutide 1.0 mg vs once-daily liraglutide 1.2 mg as add-on to 1\u20133 oral antidiabetic drugs in subjects with type 2 diabetes (SUSTAIN 10)","volume":"46","author":"Capehorn","year":"2020","journal-title":"Diabetes Metab."},{"key":"10.1016\/j.phrs.2023.107031_bib32","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1016\/S2213-8587(17)30013-X","article-title":"Efficacy and safety of once-weekly semaglutide monotherapy versus placebo in patients with type 2 diabetes (SUSTAIN 1): a double-blind, randomised, placebo-controlled, parallel-group, multinational, multicentre phase 3a trial","volume":"5","author":"Sorli","year":"2017","journal-title":"Lancet Diabetes Endocrinol."},{"key":"10.1016\/j.phrs.2023.107031_bib33","doi-asserted-by":"crossref","first-page":"834","DOI":"10.1016\/S2213-8587(19)30311-0","article-title":"Efficacy and safety of once-weekly semaglutide versus daily canagliflozin as add-on to metformin in patients with type 2 diabetes (SUSTAIN 8): a double-blind, phase 3b, randomised controlled trial","volume":"7","author":"Lingvay","year":"2019","journal-title":"Lancet Diabetes Endocrinol."},{"key":"10.1016\/j.phrs.2023.107031_bib34","doi-asserted-by":"crossref","first-page":"258","DOI":"10.2337\/dc17-0417","article-title":"Efficacy and safety of once-weekly semaglutide versus exenatide ER in subjects with type 2 diabetes (SUSTAIN 3): a 56-week, open-label, randomized clinical trial","volume":"41","author":"Ahmann","year":"2018","journal-title":"Diabetes Care"},{"key":"10.1016\/j.phrs.2023.107031_bib35","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1016\/S2213-8587(17)30085-2","volume":"5","author":"Aroda","year":"2017","journal-title":"Lancet Diabetes Endocrinol."},{"key":"10.1016\/j.phrs.2023.107031_bib36","doi-asserted-by":"crossref","first-page":"404","DOI":"10.1111\/dom.14232","article-title":"Efficacy and safety of once\u2010weekly semaglutide versus once\u2010daily sitagliptin as add\u2010on to metformin in patients with type 2 diabetes in SUSTAIN China: a 30\u2013week, double\u2010blind, phase 3a, randomized trial","volume":"23","author":"Ji","year":"2021","journal-title":"Diabetes Obes. Metab."},{"key":"10.1016\/j.phrs.2023.107031_bib37","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1016\/S2213-8587(19)30192-5","article-title":"Efficacy and safety of oral semaglutide in patients with type 2 diabetes and moderate renal impairment (PIONEER 5): a placebo-controlled, randomised, phase 3a trial","volume":"7","author":"Mosenzon","year":"2019","journal-title":"Lancet Diabetes Endocrinol."},{"key":"10.1016\/j.phrs.2023.107031_bib38","doi-asserted-by":"crossref","first-page":"528","DOI":"10.1016\/S2213-8587(19)30194-9","article-title":"Efficacy and safety of oral semaglutide with flexible dose adjustment versus sitagliptin in type 2 diabetes (PIONEER 7): a multicentre, open-label, randomised, phase 3a trial","volume":"7","author":"Pieber","year":"2019","journal-title":"Lancet Diabetes Endocrinol."},{"key":"10.1016\/j.phrs.2023.107031_bib39","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1016\/S2213-8587(22)00188-7","article-title":"Efficacy and safety of tirzepatide monotherapy compared with dulaglutide in Japanese patients with type 2 diabetes (SURPASS J-mono): a double-blind, multicentre, randomised, phase 3 trial","volume":"10","author":"Inagaki","year":"2022","journal-title":"Lancet Diabetes Endocrinol."},{"key":"10.1016\/j.phrs.2023.107031_bib40","doi-asserted-by":"crossref","first-page":"938","DOI":"10.1111\/dom.13979","volume":"22","author":"Frias","year":"2020","journal-title":"Diabetes Obes. Metab."},{"key":"10.1016\/j.phrs.2023.107031_bib41","doi-asserted-by":"crossref","first-page":"2262","DOI":"10.2337\/dc19-0898","article-title":"Efficacy, safety, and tolerability of oral semaglutide versus placebo added to insulin with or without metformin in patients with type 2 diabetes: the PIONEER 8 trial","volume":"42","author":"Zinman","year":"2019","journal-title":"Diabetes Care"},{"key":"10.1016\/j.phrs.2023.107031_bib42","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1016\/S0140-6736(21)01443-4","article-title":"Once-weekly tirzepatide versus once-daily insulin degludec as add-on to metformin with or without SGLT2 inhibitors in patients with type 2 diabetes (SURPASS-3): a randomised, open-label, parallel-group, phase 3 trial","volume":"398","author":"Ludvik","year":"2021","journal-title":"Lancet"},{"key":"10.1016\/j.phrs.2023.107031_bib43","doi-asserted-by":"crossref","first-page":"2272","DOI":"10.2337\/dc19-0883","article-title":"Oral semaglutide versus empagliflozin in patients with type 2 diabetes uncontrolled on metformin: the PIONEER 2 trial","volume":"42","author":"Rodbard","year":"2019","journal-title":"Diabetes Care"},{"key":"10.1016\/j.phrs.2023.107031_bib44","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/S0140-6736(19)31271-1","article-title":"Oral semaglutide versus subcutaneous liraglutide and placebo in type 2 diabetes (PIONEER 4): a randomised, double-blind, phase 3a trial","volume":"394","author":"Pratley","year":"2019","journal-title":"Lancet"},{"key":"10.1016\/j.phrs.2023.107031_bib45","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1016\/S2213-8587(17)30092-X","article-title":"Efficacy and safety of once-weekly semaglutide versus once-daily sitagliptin as an add-on to metformin, thiazolidinediones, or both, in patients with type 2 diabetes (SUSTAIN 2): a 56-week, double-blind, phase 3a, randomised trial","volume":"5","author":"Ahr\u00e9n","year":"2017","journal-title":"Lancet Diabetes Endocrinol."},{"key":"10.1016\/j.phrs.2023.107031_bib46","doi-asserted-by":"crossref","first-page":"1724","DOI":"10.2337\/dc19-0749","article-title":"PIONEER 1: Randomized clinical trial of the efficacy and safety of oral semaglutide monotherapy in comparison with placebo in patients with type 2 diabetes","volume":"42","author":"Aroda","year":"2019","journal-title":"Diabetes Care"},{"key":"10.1016\/j.phrs.2023.107031_bib47","doi-asserted-by":"crossref","first-page":"1202","DOI":"10.1111\/dom.13218","article-title":"Safety and efficacy of once\u2010weekly semaglutide vs additional oral antidiabetic drugs in Japanese people with inadequately controlled type 2 diabetes: a randomized trial","volume":"20","author":"Kaku","year":"2018","journal-title":"Diabetes Obes. Metab."},{"key":"10.1016\/j.phrs.2023.107031_bib48","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1016\/S2213-8587(20)30074-7","article-title":"Safety and efficacy of oral semaglutide versus dulaglutide in Japanese patients with type 2 diabetes (PIONEER 10): an open-label, randomised, active-controlled, phase 3a trial","volume":"8","author":"Yabe","year":"2020","journal-title":"Lancet Diabetes Endocrinol."},{"key":"10.1016\/j.phrs.2023.107031_bib49","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1111\/dom.13082","article-title":"Safety and efficacy of semaglutide once weekly vs sitagliptin once daily, both as monotherapy in Japanese people with type 2 diabetes","volume":"20","author":"Seino","year":"2018","journal-title":"Diabetes Obes. Metab."},{"key":"10.1016\/j.phrs.2023.107031_bib50","doi-asserted-by":"crossref","first-page":"971","DOI":"10.1016\/S0140-6736(21)00213-0","article-title":"Semaglutide 2\u00b74 mg once a week in adults with overweight or obesity, and type 2 diabetes (STEP 2): a randomised, double-blind, double-dummy, placebo-controlled, phase 3 trial","volume":"397","author":"Davies","year":"2021","journal-title":"Lancet"},{"key":"10.1016\/j.phrs.2023.107031_bib51","doi-asserted-by":"crossref","first-page":"2291","DOI":"10.1210\/jc.2018-00070","article-title":"Semaglutide added to basal insulin in type 2 diabetes (SUSTAIN 5): a randomized, controlled trial","volume":"103","author":"Rodbard","year":"2018","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"10.1016\/j.phrs.2023.107031_bib52","doi-asserted-by":"crossref","first-page":"1834","DOI":"10.1056\/NEJMoa1607141","article-title":"Semaglutide and cardiovascular outcomes in patients with type 2 diabetes","volume":"375","author":"Marso","year":"2016","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.phrs.2023.107031_bib53","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1016\/S2213-8587(19)30066-X","article-title":"Semaglutide once weekly as add-on to SGLT-2 inhibitor therapy in type 2 diabetes (SUSTAIN 9): a randomised, placebo-controlled trial","volume":"7","author":"Zinman","year":"2019","journal-title":"Lancet Diabetes Endocrinol."},{"key":"10.1016\/j.phrs.2023.107031_bib54","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1016\/S2213-8587(18)30024-X","article-title":"Semaglutide versus dulaglutide once weekly in patients with type 2 diabetes (SUSTAIN 7): a randomised, open-label, phase 3b trial","volume":"6","author":"Pratley","year":"2018","journal-title":"Lancet Diabetes Endocrinol."},{"key":"10.1016\/j.phrs.2023.107031_bib55","doi-asserted-by":"crossref","first-page":"1811","DOI":"10.1016\/S0140-6736(21)02188-7","article-title":"Tirzepatide versus insulin glargine in type 2 diabetes and increased cardiovascular risk (SURPASS-4): a randomised, open-label, parallel-group, multicentre, phase 3 trial","volume":"398","author":"Del Prato","year":"2021","journal-title":"Lancet"},{"key":"10.1016\/j.phrs.2023.107031_bib56","doi-asserted-by":"crossref","first-page":"841","DOI":"10.1056\/NEJMoa1901118","article-title":"Oral semaglutide and cardiovascular outcomes in patients with type 2 diabetes","volume":"381","author":"Husain","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.phrs.2023.107031_bib57","doi-asserted-by":"crossref","first-page":"231","DOI":"10.2337\/dc15-0165","article-title":"A phase 2, randomized, dose-finding study of the novel once-weekly human GLP-1 analog, semaglutide, compared with placebo and open-label liraglutide in patients with type 2 diabetes","volume":"39","author":"Nauck","year":"2016","journal-title":"Diabetes Care"},{"key":"10.1016\/j.phrs.2023.107031_bib58","unstructured":"ClinicalTrials.gov., A. Research Study Comparing a New Medicine Oral Semaglutide to Placebo in People With Type 2 Diabetes (PIONEER 11), https:\/\/www.clinicaltrials.gov\/study\/NCT04109547?term=NCT04109547&rank=1 (Accessed 3 Apr. 2023)."},{"key":"10.1016\/j.phrs.2023.107031_bib59","doi-asserted-by":"crossref","first-page":"1926","DOI":"10.2337\/dc17-2381","article-title":"A 26-week randomized controlled trial of semaglutide once daily versus liraglutide and placebo in patients with type 2 diabetes suboptimally controlled on diet and exercise with or without metformin","volume":"41","author":"Lingvay","year":"2018","journal-title":"Diabetes Care"},{"key":"10.1016\/j.phrs.2023.107031_bib60","article-title":"Effect of tirzepatide on glycaemic control and weight loss compared with other glucagon\u2010like peptide\u20101 receptor agonists in Japanese patients with type 2 diabetes mellitus","author":"Tsukamoto","year":"2023","journal-title":"Diabetes Obes. Metab."},{"key":"10.1016\/j.phrs.2023.107031_bib61","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1016\/S2213-8587(22)00085-7","article-title":"Effects of subcutaneous tirzepatide versus placebo or semaglutide on pancreatic islet function and insulin sensitivity in adults with type 2 diabetes: a multicentre, randomised, double-blind, parallel-arm, phase 1 clinical trial","volume":"10","author":"Heise","year":"2022","journal-title":"Lancet Diabetes Endocrinol."},{"key":"10.1016\/j.phrs.2023.107031_bib62","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1038\/s41591-022-01707-4","article-title":"Tirzepatide cardiovascular event risk assessment: a pre-specified meta-analysis","volume":"28","author":"Sattar","year":"2022","journal-title":"Nat. Med."},{"key":"10.1016\/j.phrs.2023.107031_bib63","doi-asserted-by":"crossref","first-page":"1481","DOI":"10.2337\/dc10-2415","article-title":"Benefits of modest weight loss in improving cardiovascular risk factors in overweight and obese individuals with type 2 diabetes","volume":"34","author":"Wing","year":"2011","journal-title":"Diabetes Care"}],"container-title":["Pharmacological Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1043661823003870?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1043661823003870?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,19]],"date-time":"2025-10-19T22:49:11Z","timestamp":1760914151000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1043661823003870"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,1]]},"references-count":63,"alternative-id":["S1043661823003870"],"URL":"https:\/\/doi.org\/10.1016\/j.phrs.2023.107031","relation":{},"ISSN":["1043-6618"],"issn-type":[{"value":"1043-6618","type":"print"}],"subject":[],"published":{"date-parts":[[2024,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Evaluation and comparison of efficacy and safety of tirzepatide and semaglutide in patients with type 2 diabetes mellitus: A Bayesian network meta-analysis","name":"articletitle","label":"Article Title"},{"value":"Pharmacological Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.phrs.2023.107031","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"107031"}}